Document Detail


The effect of acetyl-L-carnitine administration on persons with Down syndrome.
MedLine Citation:
PMID:  16621446     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Since previous investigations reported improvements in cognition of patients with dementia after acetyl-L-carnitine therapy and since there is an increased risk for persons with Down syndrome to develop Alzheimer disease, this study was designed to investigate the effect of acetyl-L-carnitine administration on neurological, intellectual, and social functions in adults with Down syndrome. In this double-blind study we enrolled 40 individuals with Down syndrome and administered acetyl-L-carnitine to the study group during a six months period. Specified examinations and psychological tests were given to persons in both the study and control groups at the start of the investigation and at 3, 6, and 9 months. A detailed analysis of the data revealed that acetyl-L-carnitine administration did not enhance central nervous system functions and that it did not benefit persons with Down syndrome.
Authors:
Siegfried M Pueschel
Related Documents :
19394256 - Deficiency in n-acetylgalactosamine-6-sulfate sulfatase results in collagen perturbatio...
6334486 - Tetrasomy 18p: a distinctive syndrome.
20948036 - Mutilating acral keratoderma.
9158226 - Validation of the amphetamine dependence syndrome and the samdq.
20687506 - Muir-torre syndrome.
7443046 - Trigeminal neuralgia due to dolichoectasia: angiographic and ct findings in a patient w...
Publication Detail:
Type:  Journal Article; Randomized Controlled Trial     Date:  2006-04-18
Journal Detail:
Title:  Research in developmental disabilities     Volume:  27     ISSN:  0891-4222     ISO Abbreviation:  Res Dev Disabil     Publication Date:    2006 Nov-Dec
Date Detail:
Created Date:  2006-10-03     Completed Date:  2007-01-18     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  8709782     Medline TA:  Res Dev Disabil     Country:  United States    
Other Details:
Languages:  eng     Pagination:  599-604     Citation Subset:  IM    
Affiliation:
Child Development Center, Department of Pediatrics, Rhode Island Hospital, Brown University School of Medicine, Providence, RI, USA. sigpueschel@aol.com
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Acetylcarnitine / administration & dosage*
Adult
Alzheimer Disease / drug therapy
Attention / drug effects
Cognition / drug effects*
Down Syndrome / drug therapy*
Follow-Up Studies
Humans
Intelligence Tests
Male
Nootropic Agents / administration & dosage*
Social Behavior
Treatment Failure
Wechsler Scales
Chemical
Reg. No./Substance:
0/Nootropic Agents; 14992-62-2/Acetylcarnitine

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  The role of phosphodiesterase isoforms 2, 5, and 9 in the regulation of NO-dependent and NO-independ...
Next Document:  Elevated levels of soluble CD40 ligand (sCD40L) in serum of patients with systemic autoimmune diseas...